Cirsium Biosciences Ramps Up Plant-Based AAV Scale-Up and Bolsters Quality Leadership

Cirsium Biosciences continued to advance its plant-based adeno-associated virus (AAV) manufacturing platform this week, highlighting both custom hardware and growing operational sophistication. The company reported internal development of proprietary “infiltrator” equipment, evolving from a 2022 manual device handling five plants to an automated system targeting batches of more than 100 plants.

This scale-up is intended to improve throughput, process control, and cost efficiency, supporting potential future roles in gene therapy supply chains and contract manufacturing. Cirsium also showcased its AAV workflow, from plant growth through post-infiltration expression and homogenized biomass, underscoring a defined, repeatable process rather than new clinical or regulatory milestones.

In parallel, the company is automating an early-stage tray seeding step, aiming to cut processing times from hours to minutes while maintaining precision. Management positions this automation as a way to boost speed, consistency, and scalability, potentially reducing labor intensity as production volumes rise.

To support this operational ramp-up, Cirsium expanded its leadership and support ranks across quality, facilities, and operations. New senior appointments include a Senior Director of Quality Assurance with more than 35 years of experience in pharmaceuticals and life sciences, and a Senior Director of Operations overseeing operational, financial, and technology infrastructure.

Additional hires include a Facility Manager to oversee production facilities, vertical farms, and integrated processes, as well as a Lab Aide focused on lab throughput and routine workflows. These additions suggest preparation for more complex manufacturing activity and emphasize quality systems and operational resilience as the company scales.

Cirsium also highlighted the profile of Scientist I Matthew Kohls, whose three decades of life sciences experience underscore the depth of internal scientific talent. The focus on seasoned researchers and specialized operational leaders may strengthen the company’s ability to address complex R&D and manufacturing challenges.

Collectively, this week’s updates point to steady, infrastructure-focused progress rather than external inflection points such as financings or partnerships. The buildout of proprietary equipment, automation, and quality leadership appears aimed at de-risking scale-up and positioning Cirsium Biosciences for eventual commercialization opportunities in plant-based AAV manufacturing.